Infant Bacterial Therapeutics AB Class B

As of June 30, 2026, Infant Bacterial Therapeutics AB Class B carries a market capitalization of 943.00M, placing it among publicly traded companies globally. Its enterprise value stands at 834.40M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Infant Bacterial Therapeutics AB Class B's next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, Infant Bacterial Therapeutics AB Class B has 13.47M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Infant Bacterial Therapeutics AB Class B maintains a current ratio of 1.67, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Infant Bacterial Therapeutics AB Class B posted a negative return on equity (ROE) of -87.44, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -52.27, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 8.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Infant Bacterial Therapeutics AB Class B's stock has gained approximately 34.65% over the past 52 weeks. The 50-day moving average sits at 68.92, while the 200-day moving average is 59.35.

Over the twelve months ended June 30, 2026, Infant Bacterial Therapeutics AB Class B generated - - in revenue and converted that into -81.92M in net income, yielding earnings per share of -6.08. EBITDA reached -84.17M, while operating income came in at -84.98M.

These figures are as of June 30, 2026. Total book value stands at 53.03M, with working capital of 45.29M providing operational flexibility.

Infant Bacterial Therapeutics AB Class B produced -64.06M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -6.79: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

Infant Bacterial Therapeutics AB Class B's most recent stock split took place on January 11, 2018 with a 776:867 split ratio.

As of June 30, 2026, Infant Bacterial Therapeutics AB Class B has an Altman Z-Score of -2.54, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.